We are live on ! Find out more
CNSP icon

CNS Pharmaceuticals
CNSP

1 hedge funds and large institutions have $589K invested in CNS Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 1 → 1 (0)

0% less ownership

Funds ownership: 0% → 0% (-0%)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

29% less capital invested

Capital invested by funds: $828K → $589K (-$239K)

Holders
1
Holders Change
–
Holders Change %
0%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$422K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$422K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$8K
3
Morgan Stanley
Morgan Stanley
New York
-$4K
4
UBS Group
UBS Group
Switzerland
-$3K
5
CAL
Capital Analysts LLC
Pennsylvania
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
1
Renaissance Technologies
New York
$173K +$422K +1 New
Vanguard Group
2
Vanguard Group
Pennsylvania
$146K -$422K -1 Closed
Bank of New York Mellon
3
Bank of New York Mellon
New York
$80K – – –
Geode Capital Management
4
Geode Capital Management
Massachusetts
$43K – – –
VF
5
Virtu Financial
New York
$38K – – –
Citadel Advisors
6
Citadel Advisors
Florida
$18K – – –
BFA
7
Beacon Financial Advisory
Ohio
$14K – – –
BlackRock
8
BlackRock
New York
$14K – – –
Northern Trust
9
Northern Trust
Illinois
$11K – – –
TRCT
10
Tower Research Capital (TRC)
New York
$10K – – –
Cambridge Investment Research Advisors
11
Cambridge Investment Research Advisors
Iowa
$9K – – –
Two Sigma Investments
12
Two Sigma Investments
New York
$9K – – –
State Street
13
State Street
Massachusetts
$7K – – –
Commonwealth Equity Services
14
Commonwealth Equity Services
Massachusetts
$6K – – –
HighTower Advisors
15
HighTower Advisors
Illinois
$4K – – –
Wells Fargo
16
Wells Fargo
California
$4K – – –
ACI
17
Alpha Cubed Investments
California
$3K – – –
CAL
18
Capital Analysts LLC
Pennsylvania
– -$1K – –
CA
19
CoreCap Advisors
Michigan
– -$1K – –
MIFH
20
Migdal Insurance & Financial Holdings
Israel
– -$1K – –
Morgan Stanley
21
Morgan Stanley
New York
– -$4K – –
Susquehanna International Group
22
Susquehanna International Group
Pennsylvania
– -$8K – –
UBS Group
23
UBS Group
Switzerland
– -$3K – –

CNSP Hedge Fund Activity: Q1 2022 in Review

1 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in CNS Pharmaceuticals (CNSP) for Q1 2022, worth a combined $589K — down 29% from $828K a quarter earlier.

Fund positioning in CNSP was balanced in Q1 2022: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 0 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $422K. The largest seller was Vanguard Group, exiting entirely with an estimated $422K sold.

  • 1 institutional investor held CNS Pharmaceuticals (CNSP) as of Q1 2022, unchanged from Q4 2021.
  • Funds reported $589K of CNS Pharmaceuticals stock for Q1 2022, down 29% quarter-over-quarter.
  • 1 fund opened new CNS Pharmaceuticals positions in Q1 2022 and 1 closed out, a net change of 0 holders.
  • The largest CNS Pharmaceuticals buyer in Q1 2022 was Renaissance Technologies, an estimated $422K added.
  • The largest CNS Pharmaceuticals seller in Q1 2022 was Vanguard Group, an estimated $422K sold.

Based on aggregated 13F filings for Q1 2022.